Boston Scientific Sued J&J Over Catheter Patent
The legal dispute could affect clinical workflows for cardiology practices utilizing transseptal access devices.
Updated on Oct. 9, 2026 in Healthcare
Boston Scientific filed a lawsuit in the District Court of Delaware on July 11, 2026, alleging that the Hotwire guidewire device sold by J&J subsidiary Atraverse Medical infringes on its cardiac catheterization patent. The case centers on technologies used to access the left atrium for atrial fibrillation ablation procedures.
Why it matters
The litigation creates uncertainty for clinics adopting the Hotwire system, as Boston Scientific is seeking an injunction that could potentially restrict access to the device. This dispute arises in a high-growth sector where firms are aggressively protecting intellectual property as the market expands toward an estimated $17.6 billion valuation by 2035.
The global electrophysiology ablation catheter market is projected to reach $17.6 billion by 2035, growing from a $6.1 billion valuation in 2025. This segment currently reflects a consolidated landscape where major medical device manufacturers compete for dominance in complex cardiac interventions.
The players
Boston Scientific
A global developer and manufacturer of medical devices for interventional medical specialties including cardiology and electrophysiology.
Johnson and Johnson
A multinational corporation that operates a major medical technology division, including its subsidiary Biosense Webster, which leads the U.S. electrophysiology market.
Atraverse Medical
A specialized medical device company acquired by Johnson and Johnson that produces the Hotwire radiofrequency guidewire system.
The details
The lawsuit alleges that the Hotwire system, which received FDA clearance in December 2025, utilizes radiofrequency energy in a manner that violates Patent '955 held by Boston Scientific. The complaint asserts that Atraverse Medical has actively encouraged physicians to deploy the device during transseptal catheterization in ways that infringe upon those claims. If the court grants an injunction, providers could face supply disruptions or the necessity to retrain staff on alternative access tools.
Timeline
December 2025: Atraverse Medical received FDA clearance for the Hotwire system.
April 2026: Johnson and Johnson acquired Atraverse Medical.
July 11, 2026: Boston Scientific filed the patent infringement lawsuit.
September 2026: Boston Scientific notified Atraverse Medical counsel of the alleged infringement.
October 8, 2026: The lawsuit was made public.
Market Landscape
This litigation highlights the fierce competition in the cardiac catheter market, where three firms control nearly all of the U.S. share. It follows a established industry trend where major players use intellectual property disputes to challenge new technologies from acquired entities.
Clinical operators should review their inventory and training protocols for transseptal access tools to mitigate potential disruption if an injunction is granted. Consult with your legal and procurement departments to assess whether current supplier contracts include indemnification clauses regarding intellectual property infringement.
The takeaway
Patent disputes in the medical device sector frequently signal impending product availability shifts that can force rapid clinical workflow changes. Operators should monitor the District Court of Delaware docket for any temporary restraining order rulings that could force an immediate transition to secondary device suppliers.
Further reading
For broader analysis on industry shifts, visit the Healthcare section.
